DAFNA Capital Management
Latest statistics and disclosures from DAFNA Capital Management's latest quarterly 13F-HR filing:
- Top 5 stock holdings are RVMD, XBI, STXS, ATRC, CYTK, and represent 38.99% of DAFNA Capital Management's stock portfolio.
- Added to shares of these 10 stocks: BHVN (+$8.1M), PRCT, HELP, MBX, MPLT, DNLI, PROF, BCRX, DXCM, INGN.
- Started 12 new stock positions in ACET, PROF, KPTI, PRCT, ANNX, CATX, VRCA, MPLT, HELP, FATE. RARE, ENGN.
- Reduced shares in these 10 stocks: MRUS (-$21M), AXGN (-$8.7M), XBI (-$7.9M), IBB (-$5.8M), SNDX, RCUS, RVMD, SLNO, CMPX, KRRO.
- Sold out of its positions in APRE, Biomx, BDTX, CMPX, KROS, KRRO, SLNO, Sutro Biopharma, URGN, MRUS.
- DAFNA Capital Management was a net seller of stock by $-49M.
- DAFNA Capital Management has $431M in assets under management (AUM), dropping by 6.36%.
- Central Index Key (CIK): 0001389933
Tip: Access up to 7 years of quarterly data
Positions held by DAFNA Capital Management consolidated in one spreadsheet with up to 7 years of data
Download as csv
Download as Excel
Portfolio Holdings for DAFNA Capital Management
DAFNA Capital Management holds 77 positions in its portfolio as reported in the December 2025 quarterly 13F filing
| Company (Ticker) | Portfolio Weight | Valued At | Change in Shares | Share Count | Share Price | |
|---|---|---|---|---|---|---|
| Revolution Medicines (RVMD) | 11.2 | $48M | -8% | 605k | 79.65 |
|
| Spdr S&p Biotech Etf Etf (XBI) | 9.5 | $41M | -16% | 337k | 121.93 |
|
| Stereotaxis Com New (STXS) | 7.3 | $32M | 14M | 2.30 |
|
|
| AtriCure (ATRC) | 5.5 | $24M | 597k | 39.56 |
|
|
| Cytokinetics Com New (CYTK) | 5.5 | $24M | -6% | 371k | 63.54 |
|
| Ideaya Biosciences (IDYA) | 4.1 | $18M | -6% | 507k | 34.57 |
|
| Axogen (AXGN) | 3.6 | $16M | -35% | 477k | 32.73 |
|
| Xenon Pharmaceuticals (XENE) | 3.0 | $13M | 288k | 44.82 |
|
|
| Ishares Nasdaq Biotech Indx Etf (IBB) | 2.7 | $12M | -33% | 68k | 168.77 |
|
| Biohaven (BHVN) | 2.5 | $11M | +306% | 955k | 11.29 |
|
| Arcus Biosciences Incorporated (RCUS) | 2.4 | $10M | -31% | 431k | 23.83 |
|
| Neurocrine Biosciences (NBIX) | 2.3 | $10M | 71k | 141.83 |
|
|
| Day One Biopharmaceuticals I (DAWN) | 2.2 | $9.3M | 999k | 9.32 |
|
|
| Tandem Diabetes Care Com New (TNDM) | 1.8 | $7.8M | 355k | 21.98 |
|
|
| Ascendis Pharma A/s Sponsored Adr (ASND) | 1.4 | $6.0M | -15% | 28k | 213.24 |
|
| Dex (DXCM) | 1.4 | $5.9M | +34% | 88k | 66.37 |
|
| Syndax Pharmaceuticals (SNDX) | 1.4 | $5.8M | -44% | 278k | 21.01 |
|
| Kalvista Pharmaceuticals (KALV) | 1.3 | $5.8M | -15% | 357k | 16.15 |
|
| Compass Pathways Sponsored Ads (CMPS) | 1.3 | $5.6M | 811k | 6.90 |
|
|
| Inogen (INGN) | 1.3 | $5.6M | +36% | 827k | 6.72 |
|
| Ascendis Pharma A/s Note 2.250% 4/0 (Principal) | 1.3 | $5.5M | 4.0M | 1.36 |
|
|
| Denali Therapeutics (DNLI) | 1.2 | $5.3M | +89% | 319k | 16.51 |
|
| Mbx Biosciences (MBX) | 1.2 | $5.2M | +94% | 165k | 31.54 |
|
| Bicara Therapeutics (BCAX) | 1.0 | $4.4M | -17% | 262k | 16.83 |
|
| Galapagos Nv Spon Adr (GLPG) | 1.0 | $4.3M | 130k | 32.70 |
|
|
| Astria Therapeutics | 0.9 | $4.0M | -4% | 305k | 13.09 |
|
| Edgewise Therapeutics (EWTX) | 0.9 | $4.0M | -25% | 160k | 24.82 |
|
| Immunovant (IMVT) | 0.9 | $3.8M | -21% | 151k | 25.42 |
|
| Procept Biorobotics Corp (PRCT) | 0.9 | $3.8M | NEW | 120k | 31.46 |
|
| Cybin Com New (HELP) | 0.9 | $3.7M | NEW | 455k | 8.18 |
|
| Alkermes SHS (ALKS) | 0.8 | $3.6M | -3% | 130k | 27.98 |
|
| Larimar Therapeutics (LRMR) | 0.8 | $3.6M | -8% | 939k | 3.81 |
|
| Stoke Therapeutics (STOK) | 0.8 | $3.5M | -35% | 109k | 31.74 |
|
| Lexeo Therapeutics (LXEO) | 0.8 | $3.4M | -4% | 341k | 9.93 |
|
| BioCryst Pharmaceuticals (BCRX) | 0.8 | $3.3M | +91% | 418k | 7.80 |
|
| Nektar Therapeutics Com New (NKTR) | 0.7 | $3.2M | +36% | 75k | 42.28 |
|
| Proqr Therapeutics N V Shs Euro (PRQR) | 0.7 | $3.2M | 1.6M | 2.02 |
|
|
| Century Therapeutics (IPSC) | 0.6 | $2.8M | +63% | 2.8M | 0.99 |
|
| Immatics Nv SHS (IMTX) | 0.6 | $2.7M | +11% | 261k | 10.50 |
|
| Structure Therapeutics Sponsored Ads (GPCR) | 0.6 | $2.6M | -37% | 37k | 69.55 |
|
| Maplight Therapeutics (MPLT) | 0.6 | $2.5M | NEW | 144k | 17.57 |
|
| Align Technology (ALGN) | 0.6 | $2.5M | +45% | 16k | 156.15 |
|
| Kura Oncology (KURA) | 0.6 | $2.5M | -49% | 236k | 10.39 |
|
| Aquestive Therapeutics (AQST) | 0.6 | $2.4M | -26% | 376k | 6.46 |
|
| Rapport Therapeutics (RAPP) | 0.5 | $2.3M | 75k | 30.34 |
|
|
| Profound Medical Corp Com New (PROF) | 0.5 | $2.2M | NEW | 286k | 7.87 |
|
| Silverback Therapeutics (SPRY) | 0.5 | $2.2M | +35% | 190k | 11.65 |
|
| Mediwound Shs New (MDWD) | 0.5 | $2.1M | 114k | 18.46 |
|
|
| Viking Therapeutics (VKTX) | 0.5 | $2.1M | -7% | 60k | 35.18 |
|
| Insulet Corporation (PODD) | 0.5 | $2.0M | 6.9k | 284.24 |
|
|
| Allogene Therapeutics (ALLO) | 0.4 | $1.9M | 1.4M | 1.37 |
|
|
| Celldex Therapeutics Com New (CLDX) | 0.4 | $1.9M | +179% | 69k | 27.16 |
|
| Tela Bio (TELA) | 0.4 | $1.7M | 1.4M | 1.18 |
|
|
| Engene Holdings (ENGN) | 0.3 | $1.5M | NEW | 164k | 9.03 |
|
| Verrica Pharmaceuticals Com Shs (VRCA) | 0.3 | $1.4M | NEW | 174k | 8.31 |
|
| Alector (ALEC) | 0.3 | $1.4M | +13% | 908k | 1.56 |
|
| Mineralys Therapeutics (MLYS) | 0.3 | $1.4M | -53% | 39k | 36.29 |
|
| Annexon (ANNX) | 0.3 | $1.4M | NEW | 273k | 5.02 |
|
| Oric Pharmaceuticals (ORIC) | 0.3 | $1.2M | +34% | 141k | 8.18 |
|
| Accuray Incorporated (ARAY) | 0.3 | $1.2M | +14% | 1.4M | 0.82 |
|
| Erasca (ERAS) | 0.2 | $947k | -27% | 254k | 3.72 |
|
| Polypid (PYPD) | 0.2 | $902k | 208k | 4.34 |
|
|
| Inspire Med Sys (INSP) | 0.2 | $793k | -50% | 8.6k | 92.23 |
|
| Adicet Bio Com New (ACET) | 0.2 | $790k | NEW | 94k | 8.42 |
|
| Foghorn Therapeutics (FHTX) | 0.2 | $685k | 127k | 5.40 |
|
|
| Biontech Se Sponsored Ads (BNTX) | 0.2 | $666k | 7.0k | 95.20 |
|
|
| Neurogene (NGNE) | 0.1 | $576k | -7% | 28k | 20.60 |
|
| Fate Therapeutics (FATE) | 0.1 | $540k | NEW | 550k | 0.98 |
|
| Health Sciences Acq Corp 2 (OBIO) | 0.1 | $526k | -65% | 127k | 4.15 |
|
| Bicycle Therapeutics Sponsored Ads (BCYC) | 0.1 | $457k | 65k | 7.08 |
|
|
| Compugen Ord (CGEN) | 0.1 | $417k | 272k | 1.53 |
|
|
| Karyopharm Therapeutics Com New (KPTI) | 0.1 | $375k | NEW | 51k | 7.36 |
|
| Ultragenyx Pharmaceutical (RARE) | 0.1 | $368k | NEW | 16k | 23.00 |
|
| Autolus Therapeutics Spon Ads (AUTL) | 0.1 | $357k | 179k | 1.99 |
|
|
| Adc Therapeutics Sa SHS (ADCT) | 0.1 | $272k | -36% | 77k | 3.53 |
|
| Brainsway Sponsored Ads (BWAY) | 0.1 | $247k | -77% | 13k | 19.02 |
|
| Perspective Therapeutics Com New (CATX) | 0.0 | $138k | NEW | 50k | 2.75 |
|
Past Filings by DAFNA Capital Management
SEC 13F filings are viewable for DAFNA Capital Management going back to 2010
- DAFNA Capital Management 2025 Q4 filed Feb. 17, 2026
- DAFNA Capital Management 2025 Q3 filed Nov. 14, 2025
- DAFNA Capital Management 2025 Q2 filed Aug. 14, 2025
- DAFNA Capital Management 2025 Q1 filed May 15, 2025
- DAFNA Capital Management 2024 Q4 filed Feb. 14, 2025
- DAFNA Capital Management 2024 Q3 filed Nov. 14, 2024
- DAFNA Capital Management 2024 Q2 filed Aug. 14, 2024
- DAFNA Capital Management 2024 Q1 filed May 15, 2024
- DAFNA Capital Management 2023 Q4 filed Feb. 14, 2024
- DAFNA Capital Management 2023 Q3 filed Nov. 14, 2023
- DAFNA Capital Management 2023 Q2 filed Aug. 14, 2023
- DAFNA Capital Management 2023 Q1 filed May 15, 2023
- DAFNA Capital Management 2022 Q4 filed Feb. 14, 2023
- DAFNA Capital Management 2022 Q3 filed Nov. 14, 2022
- DAFNA Capital Management 2022 Q2 filed Aug. 15, 2022
- DAFNA Capital Management 2022 Q1 filed May 16, 2022